Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner

Novo Nordisk A/S (NYSE:NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. 

Viatris Inc (NASDAQ:VTRS), via its subsidiary Mylan Pharmaceuticals, had instigated challenges aiming to pave the way for generic versions of these drugs but was thwarted by a decisive ruling from the U.S. Patent Office tribunal.

Mylan had argued that the patents were based on the anti-diabetes medication liraglutide and thus should be invalidated.

Also Read: Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?

Reinforcing Novo Nordisk's stance, Reuters noted, a spokesperson expressed the company's resolve to "vigorously defend" its intellectual property. 

Novo's Wegovy heralded as a forerunner in a novel class of efficacious weight-loss medications, has recorded flourishing sales trajectories. 

Analysts are optimistic, with projections indicating the obesity market's valuation potentially eclipsing $100 billion by the decade's closure.

Price Action: NVO shares are down 1.85% at $90.10 during the premarket session on the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.